bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Here’s What Happened

bioMerieux (OTCMKTS:BMXMF) shares gapped up prior to trading on Wednesday. The stock had previously closed at $83.27, but opened at $88.6650. bioMerieux shares last traded at $88.6650, with a volume of 51 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BMXMF shares. Zacks Research upgraded bioMerieux from a “strong sell” rating to a “hold” rating in a report on Monday. Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a research report on Friday, September 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Finally, Piper Sandler started coverage on bioMerieux in a research note on Thursday, June 11th. They issued a “neutral” rating on the stock. Five investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, bioMerieux has a consensus rating of “Reduce”.

bioMerieux Stock Up 2.4%

The firm has a fifty day moving average of $83.27 and a two-hundred day moving average of $87.43.

About bioMerieux

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.